Clinical Trials Browser

Phase 2 × Hodgkin Disease × temsirolimus × Clear all

NCT00838955 2024-07-10

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Phase 2 Terminated

Hodgkin Disease

NCT00086840 2013-01-24

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse